Characterisation and manipulation of docetaxel resistant prostate cancer cell lines

Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

(2009) C. N. Sternberg et al.   ANNALS OF ONCOLOGY

Anti- and pro-tumor functions of autophagy

(2009) Eugenia Morselli et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cellular senescence induced by aberrant MAD2 levels impacts on paclitaxel responsiveness in vitro

(2009) M Prencipe et al.   BRITISH JOURNAL OF CANCER

Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation

(2009) Catherine Gill et al.   Molecular Cancer

Dynamics and diversity in autophagy mechanisms: lessons from yeast

(2009) Hitoshi Nakatogawa et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy

(2008) Richard D. Sowery et al.   BJU INTERNATIONAL

Hypoxia increases normal prostate epithelial cell resistance to receptor-mediated apoptosisviaAKT activation

(2008) Sinead Walsh et al.   INTERNATIONAL JOURNAL OF CANCER

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY